September 24, 2017 10:10 PM ET


Company Overview of United Therapeutics Corporation

Company Overview

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhib...

1040 Spring Street

Silver Spring, MD 20910

United States

Founded in 1996

750 Employees



Key Executives for United Therapeutics Corporation

Founder, Chairman & CEO
Age: 62
Total Annual Compensation: $1.2M
President & COO
Age: 45
Total Annual Compensation: $568.4K
CFO & Treasurer
Age: 49
Total Annual Compensation: $591.0K
Executive VP, General Counsel & Corporate Secretary
Age: 53
Total Annual Compensation: $942.7K
Senior Advisor
Age: 55
Total Annual Compensation: $484.9K
Compensation as of Fiscal Year 2016.

United Therapeutics Corporation Key Developments

United Therapeutics Corporation Announces FREEDOM-EV Study of Orenitram® to Continue as Planned Following Interim Analysis

United Therapeutics Corporation announced that the independent data monitoring committee (DMC) for the FREEDOM-EV study of Orenitram (treprostinil) extended-release tablets had completed a pre-specified interim safety and efficacy analysis. The DMC did not identify any new safety concerns associated with Orenitram therapy, and recommended that the trial be continued as planned without modification. FREEDOM-EV is a Phase 3, international, multi-center, randomized, double-blind, placebo-controlled, clinicalworsening study of Orenitram in patients with pulmonary arterial hypertension (PAH) receiving background oral monotherapy study (a phosphodiesterase type 5 inhibitor or an endothelin receptor antagonist). In accordance with the study protocol and DMC charter, previous interim safety analyses were performed at scheduled intervals throughout the study and this interim safety and efficacy analysis was performed after approximately 75% of the target 205 adjudicated clinical worsening (morbidity or mortality) events occurred within the study. United Therapeutics is intentionally blinded to the interim analysis data and will remain blinded to results of the study until after the study is completed. The threshold for stopping the trial early for overwhelming efficacy was intentionally set high with the understanding that a more robust result, based on a larger number of clinical worsening (morbidity or mortality) events, could be obtained by the study continuing to completion. The DMC's recommendation to continue as planned reflects its review of all available safety and efficacy data, and was made independently. Neither United Therapeutics nor the U.S. Food and Drug Administration (FDA) has reviewed the interim clinical trial results and neither participated in the DMC's closed session deliberation.

GlaxoSmithKline Reportedly In Race To Acquire United Therapeutics

GlaxoSmithKline plc (LSE:GSK) in $9 billion race for United Therapeutics Corporation (NasdaqGS:UTHR), sources said. The sources said United Therapeutics is likely to fetch up to $200 a share, meaning any bidder could pay around $8.7 billion. Gilead Sciences, Inc. (NasdaqGS:GILD) is thought to be the frontrunner for United Therapeutics in what could become an auction process. Other names in the frame include Novartis AG (SWX:NOVN). Gilead Sciences GlaxoSmithKline, which is thought to be being advised by Lazard and Citi, might be among the contenders, but it would face stiff competition from rivals, the sources added. Glaxo and United declined to comment.

United Therapeutics Corporation Presents at Wedbush PacGrow Healthcare Conference, Aug-15-2017 01:55 PM

United Therapeutics Corporation Presents at Wedbush PacGrow Healthcare Conference, Aug-15-2017 01:55 PM. Venue: Le Parker Meridien Hotel, 119 West 56th St., New York, New York, United States. Speakers: Martine A. Rothblatt, Founder, Chairman of the Board and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
August 21, 2017
Celularity, Inc.
April 28, 2017
Private Placement
April 12, 2017
Respira Therapeutics, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact United Therapeutics Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at